230 selected records with a cited source date in 2017, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT02588716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-27, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00734279 at 2026-11-15T22:03:26.540Z. Its registry update date was 2017-12-26, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained PubMed bibliographic metadata for PMID 27894941 at 2026-07-30T21:22:58.009Z. PubMed recorded a metadata revision date of 2017-12-23 and an Entrez history date of 2016-11-30. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide.
The official Drugs@FDA dataset lists original submission 1 for NDA 208374 with status AP dated 2017-12-21, and names bivalirudin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02718599 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-19, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT01705587 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-12-12, and PeptideScanner's reviewed identity mapping was teriparatide.
The official Drugs@FDA dataset lists original submission 1 for NDA 209637 with status AP dated 2017-12-05, and names semaglutide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00433966 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-12-04, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT02079870 at 2026-07-30T21:22:00.245Z. Its registry update date was 2017-12-02, and PeptideScanner's reviewed identity mapping was semaglutide.
The Federal Register published notice 2017-25920, attributed to FDA and its parent HHS department, on 2017-12-01. Its official title is “Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02745470 at 2026-07-30T21:22:00.254Z. Its registry update date was 2017-11-29, and PeptideScanner's reviewed identity mapping was lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00596934 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01588418 at 2026-07-30T21:22:00.248Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was exenatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206551 with status AP dated 2017-11-22, and names bivalirudin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01762943 at 2026-07-30T21:22:00.263Z. Its registry update date was 2017-11-20, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02102204 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-11-17, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PubMed lists PMID 11184472 in Clinical pharmacology and therapeutics as Journal Article, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 19954433 in Chemical biology & drug design as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-01 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-6. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 21816551 in Forensic science international as Journal Article, with publication-date metadata of 2011-08-03 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23675762 in Expert opinion on pharmacotherapy as Editorial, with publication-date metadata of 2013-05-16 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 25581107 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2015-01-19 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 27279382 in Drug testing and analysis as Journal Article, with publication-date metadata of 2016-06-09 (day precision). PeptideScanner associated the retained record with the identity slug peginesatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 6398312 in International journal of clinical pharmacology research as Clinical Trial, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1984 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 7485786 in Akusherstvo i ginekologiia as Journal Article, with publication-date metadata of 1994 (year precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23249729 in The Annals of pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2012-12-18 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23464519 in Future medicinal chemistry as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2013-03 (month precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 24227771 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2013-11 (month precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 24486708 in European journal of pharmacology as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-01-31 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 25333331 in Journal of medical economics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-04 (month precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 25912999 in Experimental eye research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-04-24 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 27060013 in European journal of pharmacology as Journal Article, with publication-date metadata of 2016-04-06 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 27815173 in European journal of pharmacology as Journal Article, with publication-date metadata of 2016-11-01 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 12101568 at 2026-07-30T21:22:56.967Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2002-07-10. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 15381050 at 2026-07-30T21:22:56.969Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2004-09-24. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 15774286 at 2026-07-30T21:22:56.970Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2005-03-19. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 15840402 at 2026-07-30T21:22:56.970Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2005-04-21. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 16117343 at 2026-07-30T21:22:56.971Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2005-08-25. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 16369461 at 2026-07-30T21:22:56.972Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2005-12-22. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 16583442 at 2026-07-30T21:22:56.973Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2006-04-04. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 16609979 at 2026-07-30T21:22:56.973Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2006-04-13. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 17694454 at 2026-07-30T21:22:56.977Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2007-08-19. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 18594781 at 2026-07-30T21:22:56.978Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-07-03. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 19098860 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-12-23. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 19465062 at 2026-07-30T21:22:56.982Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2009-05-26. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 19706070 at 2026-07-30T21:22:57.963Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2009-08-27. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 19903499 at 2026-07-30T21:22:57.965Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2009-11-12. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 19931318 at 2026-07-30T21:22:57.965Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2009-11-26. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 20190676 at 2026-07-30T21:22:57.967Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2010-03-02. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 20560145 at 2026-07-30T21:22:57.971Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2010-06-19. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 22050344 at 2026-07-30T21:22:57.978Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2011-11-05. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 25402764 at 2026-07-30T21:22:57.992Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2014-11-18. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 26979527 at 2026-07-30T21:22:57.999Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2016-03-17. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 11742568 at 2026-07-30T21:22:56.965Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2001-12-18. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 11978191 at 2026-07-30T21:22:56.966Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2002-04-30. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 14554208 at 2026-07-30T21:22:56.968Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2003-10-14. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 17575575 at 2026-07-30T21:22:56.977Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 18690162 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-12. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 18724445 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-30. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 18828236 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-10-03. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 23407924 at 2026-07-30T21:22:57.984Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2013-02-15. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 23884489 at 2026-07-30T21:22:57.985Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2013-07-26. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 25230094 at 2026-07-30T21:22:57.990Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2014-09-18. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 25470471 at 2026-07-30T21:22:57.992Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2014-12-04. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 21073357 at 2026-07-30T21:22:57.974Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2010-11-16. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 21597671 at 2026-07-30T21:22:57.976Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2011-05-21. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 23277150 at 2026-07-30T21:22:57.983Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2013-01-02. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT03061604 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-14, and PeptideScanner's reviewed identity mapping was octreotide.
PubMed lists PMID 27756786 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-10-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 205557 with status AP dated 2017-11-06, and names eptifibatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 17 for the reviewed Linaclotide label family with a published date of 2017-11-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00781937 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01557166 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00089570 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT02647944 at 2026-07-30T21:22:00.265Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was liraglutide.
DailyMed lists Structured Product Labeling version 25 for the reviewed Dulaglutide label family with a published date of 2017-10-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 209949 with status AP dated 2017-10-20, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 209210 with status AP dated 2017-10-20, and names exenatide synthetic among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02351128 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-10-18, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained PubMed bibliographic metadata for PMID 16839319 at 2026-07-30T21:22:56.974Z. PubMed recorded a metadata revision date of 2017-10-16 and an Entrez history date of 2006-07-15. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00223717 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-10-13, and PeptideScanner's reviewed identity mapping was desmopressin.
DailyMed lists Structured Product Labeling version 5 for the reviewed Lixisenatide label family with a published date of 2017-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01402336 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-10-10, and PeptideScanner's reviewed identity mapping was cetrorelix.
DailyMed lists Structured Product Labeling version 2 for the reviewed Abaloparatide label family with a published date of 2017-10-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00589472 at 2026-07-30T21:22:00.251Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01969149 at 2026-07-30T21:22:00.262Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was exenatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091345 with status AP dated 2017-10-03, and names desmopressin acetate among the application record's active ingredients.
The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The Federal Register published notice 2017-21202, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide and Teriparatide.
PubMed lists PMID 27774662 in Reproduction in domestic animals = Zuchthygiene as Journal Article, with publication-date metadata of 2016-10-23 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.
The official Drugs@FDA dataset lists original submission 1 for NDA 208385 with status AP dated 2017-09-12, and names daptomycin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00456885 at 2026-07-30T21:23:14.762Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00295178 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-09-07, and PeptideScanner's reviewed identity mapping was daptomycin.
DailyMed lists Structured Product Labeling version 4 for the reviewed Lixisenatide label family with a published date of 2017-09-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 23 for the reviewed Dulaglutide label family with a published date of 2017-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT02321878 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-09-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02516150 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-08-31, and PeptideScanner's reviewed identity mapping was glucagon.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204695 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204751 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02474914 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-08-22, and PeptideScanner's reviewed identity mapping was octreotide.
DailyMed lists Structured Product Labeling version 22 for the reviewed Dulaglutide label family with a published date of 2017-08-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2017-16581, attributed to FDA and its parent HHS department, on 2017-08-07. Its official title is “Product-Specific Guidances; Final Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01153425 at 2026-07-30T21:23:14.757Z. Its registry update date was 2017-08-04, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01467882 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-07-28, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00978393 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01552343 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-07-11, and PeptideScanner's reviewed identity mapping was desmopressin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204876 with status AP dated 2017-07-06, and names bivalirudin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 16 for the reviewed Linaclotide label family with a published date of 2017-07-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT02273115 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00600886 at 2026-07-30T21:23:14.761Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was octreotide.
The official Drugs@FDA dataset lists original submission 1 for NDA 208956 with status AP dated 2017-06-29, and names triptorelin pamoate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 21 for the reviewed Dulaglutide label family with a published date of 2017-06-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT02508103 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-06-27, and PeptideScanner's reviewed identity mapping was oxytocin.
DailyMed lists Structured Product Labeling version 15 for the reviewed Linaclotide label family with a published date of 2017-06-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02291679 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-06-15, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01679197 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide.
DailyMed lists Structured Product Labeling version 14 for the reviewed Linaclotide label family with a published date of 2017-06-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00140231 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-07, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02125188 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01023061 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02223429 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-06-05, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00225420 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-06-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01652573 at 2026-11-15T21:54:02.201Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.
PeptideScanner retained PubMed bibliographic metadata for PMID 28160873 at 2026-07-30T21:25:18.679Z. PubMed recorded a metadata revision date of 2017-05-31 and an Entrez history date of 2017-02-06. PeptideScanner associated this retained record with the identity slug abaloparatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01431391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-30, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained PubMed bibliographic metadata for PMID 12168778 at 2026-07-30T21:25:18.666Z. PubMed recorded a metadata revision date of 2017-05-29 and an Entrez history date of 2002-08-10. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.
The official Drugs@FDA dataset lists original submission 1 for ANDA 207880 with status AP dated 2017-05-26, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 201577 with status AP dated 2017-05-26, and names bivalirudin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02107391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-24, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00919802 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-05-23, and PeptideScanner's reviewed identity mapping was oxytocin.
The Federal Register published notice 2017-10326, attributed to FDA and its parent HHS department, on 2017-05-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02311231 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-05-19, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00130117 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-05-17, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT00170157 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00759772 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-05-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01637272 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-05-10, and PeptideScanner's reviewed identity mapping was pasireotide.
DailyMed lists Structured Product Labeling version 1 for the reviewed Abaloparatide label family with a published date of 2017-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01739049 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-05-04, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01302392 at 2026-11-16T17:39:29.005Z. Its registry update date was 2017-05-02, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01565265 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-05-01, and PeptideScanner's reviewed identity mapping was cetrorelix.
The official Drugs@FDA dataset lists original submission 1 for NDA 208743 with status AP dated 2017-04-28, and names abaloparatide among the application record's active ingredients.
PubMed lists PMID 17380212 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2007-03 (month precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 16845440 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2006-06 (month precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT02916251 at 2026-11-16T01:42:39.027Z. Its registry update date was 2017-04-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204589 with status AP dated 2017-04-18, and names eptifibatide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01134549 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT00672074 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was ipamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT02135445 at 2026-11-15T21:52:09.579Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01280344 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was ipamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01414114 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT00182754 at 2026-07-30T21:24:24.234Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00650546 at 2026-07-30T21:24:24.230Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01400516 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01155180 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01651780 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT01994330 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00380406 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02022254 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-04-04, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00332969 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-03-31, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01438086 at 2026-11-16T17:35:13.282Z. Its registry update date was 2017-03-30, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT00358579 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-03-17, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01888120 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-03-16, and PeptideScanner's reviewed identity mapping was ziconotide.
PeptideScanner retained ClinicalTrials.gov record NCT00947752 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-03-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PubMed lists PMID 27123689 in Expert review of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2016-05-13 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 25715416 at 2026-07-30T21:26:46.054Z. PubMed recorded a metadata revision date of 2017-03-08 and an Entrez history date of 2015-02-26. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.
PubMed lists PMID 9640081 in Polskie Archiwum Medycyny Wewnetrznej as Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 1997-12 (month precision). PeptideScanner associated the retained record with the identity slug calcitonin-salmon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for NDA 201656 with status AP dated 2017-03-03, and names desmopressin acetate among the application record's active ingredients.
PubMed lists PMID 11526758 in Ginekologia polska as Clinical Trial, English Abstract, Journal Article, with publication-date metadata of 2001-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT01484873 at 2026-07-30T21:25:36.820Z. Its registry update date was 2017-03-03, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00855439 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03068065 at 2026-07-30T21:25:36.832Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01919723 at 2026-11-15T21:59:29.646Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT01518101 at 2026-07-30T21:25:36.782Z. Its registry update date was 2017-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00171886 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-02-24, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01128894 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02325960 at 2026-07-30T21:25:37.027Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was exenatide.
PubMed lists PMID 28195861 in A & A case reports as Case Reports, Journal Article, with publication-date metadata of 2017-02-15 (day precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677.
DailyMed lists Structured Product Labeling version 13 for the reviewed Linaclotide label family with a published date of 2017-02-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.